Apnimed director reports option grants and share buy
Apnimed, Inc. director Paul J. Sekhri reported several equity awards and a share purchase.
Rhea-AI Filing Summary
Apnimed, Inc. director Paul J. Sekhri reported several equity awards and a share purchase. On 2026-08-03, he reported paired dispositions to the issuer and grants of stock options over 169,468 shares at an exercise price of $8.15 per share and options over 177,796 shares at $16.00 per share, reflecting a reclassification in which each share of Class A Common Stock became one share of Common Stock. The options vest over multi-year schedules beginning in 2026. He also purchased 12,500 shares of Common Stock at $16.00 per share on 2026-08-03, held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 12,500 shares
Net Buy
9 txns
Insider
SEKHRI PAUL J
Role
Director
Bought
12,500 shs ($200K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) F1, F2 | 169,468 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 169,468 | $0.00 | $0.00 |
| Disposition | Stock Option (Right to Buy) F1, F2 | 155,558 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 155,558 | $0.00 | $0.00 |
| Disposition | Stock Option (Right to Buy) F1, F3 | 22,238 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F1, F3 | 22,238 | $0.00 | $0.00 |
| Purchase | Common Stock | 12,500 | $16.00 | $200K |
| Grant/Award | Stock Option (Right to Buy) F2 | 155,558 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F3 | 22,238 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 502,822 contracts (Direct);
Common Stock — 12,500 shares (Direct)
Footnotes (3)
- F1. Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.
- F2. One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F3. The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Key Figures
Common Stock purchased: 12,500 shares at $16.00 per share
Option grant at $8.15: 169,468 shares at $8.15 per share
Option grants at $16.00: 177,796 shares at $16.00 per share
+2 more
5 metrics
Common Stock purchased
12,500 shares at $16.00 per share
Open-market or private purchase on 2026-08-03; held directly after transaction
Option grant at $8.15
169,468 shares at $8.15 per share
Stock option (right to buy) with expiration on 2036-05-28
Option grants at $16.00
177,796 shares at $16.00 per share
Stock options (right to buy) with expiration on 2036-07-29
Vesting start date (first grant)
June 1, 2026
One-third vests after 12 months from this date, remainder quarterly over 24 months
Vesting start date (second grant)
July 30, 2026
Vests in substantially equal monthly installments over 36 months after this date
Key Terms
Rule 16b-7, Rule 16b-3, Class A Common Stock, vest and become exercisable, +1 more
5 terms
Rule 16b-7 regulatory
"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3"
A U.S. Securities and Exchange Commission safe-harbor rule that shields corporate insiders (officers, directors and large shareholders) from automatic short-swing profit claims when they buy or sell their company’s stock under a pre-approved, written plan that follows specific timing and nondiscretionary rules. For investors, the rule matters because it distinguishes routine, formula-driven insider transactions from opportunistic trades that could trigger automatic profit recoveries—think of it as an approved autopilot for insider trading that reduces legal uncertainty when the plan’s conditions are met.
Rule 16b-3 regulatory
"reclassification exempt under Rule 16b-7 and Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
Class A Common Stock financial
"each share of Class A Common Stock was reclassified into one share"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
vest and become exercisable financial
"shares subject to such option vest and become exercisable when the Reporting Person"
substantially equal monthly installments financial
"vest and become exercisable in substantially equal monthly installments"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Apnimed (APMD) director Paul J. Sekhri report?
Paul J. Sekhri reported multiple stock option grants and related dispositions to the issuer, plus a purchase of 12,500 Common Shares at $16.00 on 2026-08-03. The options cover shares at $8.15 and $16.00 exercise prices.
What stock options were granted to Paul J. Sekhri by Apnimed (APMD)?
He was granted stock options covering 169,468 shares at $8.15 and options covering an additional 177,796 shares at $16.00. These options relate to Common Stock following a reclassification of Class A Common Stock into Common Stock.
What are the vesting terms of Paul J. Sekhri’s Apnimed (APMD) options?
For one grant, one‑third vests after 12 months from June 1, 2026, with the rest vesting quarterly over 24 months. Another grant vests in substantially equal monthly installments over 36 months after July 30, 2026, subject to continuous service.
What reclassification did Apnimed (APMD) disclose in connection with this Form 4?
The company disclosed that, under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. The reported option transactions reflect this share reclassification.
AI-generated analysis. How Rhea-AI works. Not financial advice.
